Med. praxi. 2023;20(5):282-290 | DOI: 10.36290/med.2023.044
Anticoagulation therapy
- Trombotické centrum, Ústav lékařské biochemie a laboratorní diagnostiky, Všeobecná fakultní nemocnice v Praze
Anticoagulation therapy prevents the generation of thrombin and the subsequent conversion of fibrinogen to fibrin by various mechanisms. Heparin is a parenterally administered anticoagulant that indirectly blocks the thrombotic effect of thrombin after activation of antithrombin. Injectable anticoagulants also include low-molecular-weight heparins (LMWH) and fondaparinux, which indirectly, with the participation of antithrombin, inhibit activated F Xa. Oral anticoagulants (OACs) include warfarin, which suppresses the formation of functional procoagulation factors dependent on vitamin K (prothrombin, F VII, F IX, and F X), and so-called direct oral anticoagulants (DOACs), which cause either direct inhibition of thrombin (dabigatran etexilate) or direct inhibition of activated F Xa (apixaban, edoxaban, rivaroxaban).
Keywords: thromboembolism, anticoagulants, hemostasis, low molecular weight heparins (LMWH), direct oral anticoagulants (DOAC).
Received: July 20, 2023; Revised: October 25, 2023; Accepted: October 25, 2023; Published: December 19, 2023 Show citation
References
- Čihák R, Haman L, Táborský M. Updated European Heart Rhythm Association Practical Guide on the use of non‑vitamin K antagonist anticoagulants in patients with non‑valvular atrial fibrillation: Summary of the document prepared by the Czech Society of Cardiology. Cor et Vasa. 2016;58:e153-e174.
Go to original source... - Kvasnička J, Penka M, Kvasnička T, et al. Doporučení České společnosti pro trombózu a hemostázu České lékařské společnosti J. E. Purkyně pro bezpečnou léčbu novými perorálními antikoagulancii (NOAC) - dabigatran etexilátem, apixabanem a rivaroxabanem [Guidelines of Czech Association for Thrombosis and Haemostasis of the Czech Medical Association of J. E. Purkyně for safety treatment with new oral anticoagulants (NOAC) - dabigatran etexilate, apixaban and rivaroxaban]. Vnitr Lek. 2015 Jun;61(6):537-46. Czech. PMID: 26258969.
- Kvasnička T. Antikoagulancia v ordinaci praktického lékaře. Medical Tribune. 2022;2:9-12.
- Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions. Curr Drug Metab. 2017;18(7):636-642. doi: 10.2174/1389200218666170518165443. PMID: 2852 4005. Go to original source...
Go to PubMed...